Good morning, everyone, and welcome to another working week. The weekend respite went by quickly, yes? Well, this was to be expected. After all, time never stands still. This, of course, is a good reminder to keep busy, and we are doing so with the help of a few cups of stimulation. We will interrupt our usual programming, however, at midday for an appearance on a panel, but return later to resume our usual routine. Meanwhile, here are some tidbits. Have a great day and do keep in touch …
Alexion Pharmaceuticals said its chief executive and chief financial officer have left, as a previously disclosed internal accounting investigation nears completion. Two months ago, a former employee alleged fraud in connection with its Soliris rare disease drug, which generated $2.6 billion in sales in 2015. Delayed quarterly filings are now expected next month or sooner. Board member and former AstraZeneca chief executive David Brennan will become interim CEO.
About the Author Reprints
Brennan the Barbarian back in business! GREAT! …again!
Pharmalot behind a paywalll… they did it again.
I’m out. Merry Christmas everybody!
Sorry, gotta pay to play from now on. Will miss your bile.
@vet from time to time I will try to comment on the first few lines readable for the plebs 🙂 FUN!